Sundar Jagannath1, Anuja Roy2, Jonathan Kish3, Orsolya Lunacsek4, Denise Globe2, Michael Eaddy4, Emil T Kuriakose2, Joanne Willey4, Stephanie Butler-Bird4, David Siegel5. 1. a Tisch Cancer Institute/Multiple Myeloma Program , Mt. Sinai Cancer Institute , New York , NY , USA. 2. b Global Market Access & Policy , Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA. 3. c Formerly with Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA. 4. d Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA. 5. e John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
Abstract
BACKGROUND: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. METHODS: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. RESULTS: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1(st) (11.1 months) and 2(nd) line (10.5) and decreased in lines 3 through 5 (3(rd): 7.9; 4(th): 7.2, 5(th): 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). CONCLUSIONS: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.
BACKGROUND: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. METHODS: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. RESULTS:Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1(st) (11.1 months) and 2(nd) line (10.5) and decreased in lines 3 through 5 (3(rd): 7.9; 4(th): 7.2, 5(th): 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). CONCLUSIONS: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.
Authors: Evangelos Terpos; Karthik Ramasamy; Nadjoua Maouche; Jiri Minarik; Ioannis Ntanasis-Stathopoulos; Eirini Katodritou; Matthew W Jenner; Hana Plonkova; Maria Gavriatopoulou; Grant D Vallance; Tomas Pika; Maria Kotsopoulou; Jaimal Kothari; Tomas Jelinek; Efstathios Kastritis; Robin Aitchison; Meletios A Dimopoulos; Athanasios Zomas; Roman Hajek Journal: Ann Hematol Date: 2020-04-01 Impact factor: 3.673
Authors: María-Victoria Mateos; Tamas Masszi; Norbert Grzasko; Markus Hansson; Irwindeep Sandhu; Ludek Pour; Luísa Viterbo; Sharon R Jackson; Anne-Marie Stoppa; Peter Gimsing; Mehdi Hamadani; Gabriela Borsaru; Deborah Berg; Jianchang Lin; Alessandra Di Bacco; Helgi van de Velde; Paul G Richardson; Philippe Moreau Journal: Haematologica Date: 2017-07-27 Impact factor: 9.941
Authors: Kari Remes; Pekka Anttila; Raija Silvennoinen; Mervi Putkonen; Hanna Ollikainen; Venla Terävä; Marjatta Sinisalo; Kristiina Kananen; Frida Schain; Päivi Castren-Kortegangas; Tiina M Järvinen; Marta Pisini; Felix Wahl; Tricia Dixon; Amy Leval Journal: PLoS One Date: 2018-12-05 Impact factor: 3.240
Authors: Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson Journal: Blood Cancer J Date: 2018-11-09 Impact factor: 11.037
Authors: Jesús F San-Miguel; Maria-Asunción Echeveste Gutierrez; Ivan Špicka; María-Victoria Mateos; Kevin Song; Michael D Craig; Joan Bladé; Roman Hájek; Christine Chen; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Catriona Byrne; Vickie Lu; Helgi van de Velde; Sagar Lonial Journal: Haematologica Date: 2018-06-28 Impact factor: 9.941
Authors: Thomas G Martin; Kathryn Corzo; Marielle Chiron; Helgi van de Velde; Giovanni Abbadessa; Frank Campana; Malini Solanki; Robin Meng; Helen Lee; Dmitri Wiederschain; Chen Zhu; Alexey Rak; Kenneth C Anderson Journal: Cells Date: 2019-11-26 Impact factor: 6.600
Authors: Sudhir Manda; Habte A Yimer; Stephen J Noga; Saulius Girnius; Christopher A Yasenchak; Veena Charu; Roger Lyons; Jack Aiello; Kimberly Bogard; Renda H Ferrari; Dasha Cherepanov; Brittany Demers; Vickie Lu; Presley Whidden; Suman Kambhampati; Ruemu E Birhiray; Haresh S Jhangiani; Ralph Boccia; Robert M Rifkin Journal: Clin Lymphoma Myeloma Leuk Date: 2020-07-06